Tirofiban
- IVTirofibanAggrastatShort half-life (2 hours) and effect (haemostasis 4 hours)
Mechanism of Action
- Inhibits glycoprotein IIb/IIIa receptors, preventing them from binding to plasma adhesive proteins such as fibrinogen and von Willebrand factor (vWF) and facilitating platelet adhesion.
Clinical Use
Indications
- Acute coronary syndrome
- Contraindications
- Active or recent internal bleeding
- Past ischaemic stroke with residual deficit
- Recent major trauma or surgery
- Intracranial neoplasm, AVM or aneurysm
- Past vasculitis
- Adverse Effects
- Bleeding
- Thrombocytopaenia
- Nausea / vomiting